normal huan intestinal epithelial cell line hiec Search Results


mda mb 435s  (ATCC)
96
ATCC mda mb 435s
Mda Mb 435s, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mda mb 435s/product/ATCC
Average 96 stars, based on 1 article reviews
mda mb 435s - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
epithelix sàrl  (Epithelix)
90
Epithelix epithelix sàrl
Epithelix Sàrl, supplied by Epithelix, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/epithelix sàrl/product/Epithelix
Average 90 stars, based on 1 article reviews
epithelix sàrl - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti n cadherin  (Hangzhou HuaAn Biotechnology)
90
Hangzhou HuaAn Biotechnology anti n cadherin
SERPINB5 knockdown suppresses the epithelial‐mesenchymal transition (EMT) of lung adenocarcinoma (LUAD) cells (a) Immunofluorescence staining showed the changes in the expression of EMT‐associated genes <t>E‐cadherin</t> (green) and vimentin (red) in LUAD cells. Nuclei were counterstained with DAPI (blue). (b) Western blot assay of the expression of EMT markers in LUAD cells transfected with si‐SERPINB5.
Anti N Cadherin, supplied by Hangzhou HuaAn Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti n cadherin/product/Hangzhou HuaAn Biotechnology
Average 90 stars, based on 1 article reviews
anti n cadherin - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
e cadherin  (Proteintech)
96
Proteintech e cadherin
Fig. 4 AGR2-downregulation was an invasive biomarker in PCMR. a–d The AGR2 expression of BPH-versus tumor-derived primary cell in whole cell (a, b) and surface protein (c, d) lysates was evaluated employing LC-MS/MS (a, c) and western blotting (WB, b, d). The protein blot bands of WB were quantified utilizing gray scanning (ImageJ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Wilcoxon rank-sum test. e IHC staining of AGR2 in different pathological grades (n = 138). The representative AGR2 IHC results (left) performed on Gleason score (GS) 3 + 4, GS 4 + 5, GS 5 + 5 and BPH. The positive rate of AGR2 was analyzed among BPHs (n = 37), early stage of tumors (GS 6–7, n = 80) and late stage of tumors (GS 8–10, n = 49) (right). *p < 0.05 by Fisher’s Exact test. Scale bar, 200 μm. f Kaplan–Meier plots for disease-free survival (DFS) of TCGA-PRAD patients grouped by the median of AGR2 levels. Statistics calculated by Log-rank test. g–i Scatter plots showing the Spearman’s correlation between AGR2 and three epithelium-related genes (CDH1, CTNNA1, CTNNB1) in TCGA PRAD (n = 494) database. The Spearman’s correlation was analyzed by GEPIA. j Spearman’s Correlation analysis between AGR2 and EMT-related genes (CDH1, CTNNA1, CTNNB1, EHF, VIM) in PCMR. k, l WB analysis of <t>E-cadherin,</t> Vimentin expression levels in NC/AGR2-KD PC3 cells (k) and xenograft tissues (l)
E Cadherin, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e cadherin/product/Proteintech
Average 96 stars, based on 1 article reviews
e cadherin - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
a549 huan lung carcinoma  (ATCC)
99
ATCC a549 huan lung carcinoma
Fig. 4 AGR2-downregulation was an invasive biomarker in PCMR. a–d The AGR2 expression of BPH-versus tumor-derived primary cell in whole cell (a, b) and surface protein (c, d) lysates was evaluated employing LC-MS/MS (a, c) and western blotting (WB, b, d). The protein blot bands of WB were quantified utilizing gray scanning (ImageJ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Wilcoxon rank-sum test. e IHC staining of AGR2 in different pathological grades (n = 138). The representative AGR2 IHC results (left) performed on Gleason score (GS) 3 + 4, GS 4 + 5, GS 5 + 5 and BPH. The positive rate of AGR2 was analyzed among BPHs (n = 37), early stage of tumors (GS 6–7, n = 80) and late stage of tumors (GS 8–10, n = 49) (right). *p < 0.05 by Fisher’s Exact test. Scale bar, 200 μm. f Kaplan–Meier plots for disease-free survival (DFS) of TCGA-PRAD patients grouped by the median of AGR2 levels. Statistics calculated by Log-rank test. g–i Scatter plots showing the Spearman’s correlation between AGR2 and three epithelium-related genes (CDH1, CTNNA1, CTNNB1) in TCGA PRAD (n = 494) database. The Spearman’s correlation was analyzed by GEPIA. j Spearman’s Correlation analysis between AGR2 and EMT-related genes (CDH1, CTNNA1, CTNNB1, EHF, VIM) in PCMR. k, l WB analysis of <t>E-cadherin,</t> Vimentin expression levels in NC/AGR2-KD PC3 cells (k) and xenograft tissues (l)
A549 Huan Lung Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a549 huan lung carcinoma/product/ATCC
Average 99 stars, based on 1 article reviews
a549 huan lung carcinoma - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
transition  (Cell Signaling Technology Inc)
97
Cell Signaling Technology Inc transition
Fig. 4 AGR2-downregulation was an invasive biomarker in PCMR. a–d The AGR2 expression of BPH-versus tumor-derived primary cell in whole cell (a, b) and surface protein (c, d) lysates was evaluated employing LC-MS/MS (a, c) and western blotting (WB, b, d). The protein blot bands of WB were quantified utilizing gray scanning (ImageJ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Wilcoxon rank-sum test. e IHC staining of AGR2 in different pathological grades (n = 138). The representative AGR2 IHC results (left) performed on Gleason score (GS) 3 + 4, GS 4 + 5, GS 5 + 5 and BPH. The positive rate of AGR2 was analyzed among BPHs (n = 37), early stage of tumors (GS 6–7, n = 80) and late stage of tumors (GS 8–10, n = 49) (right). *p < 0.05 by Fisher’s Exact test. Scale bar, 200 μm. f Kaplan–Meier plots for disease-free survival (DFS) of TCGA-PRAD patients grouped by the median of AGR2 levels. Statistics calculated by Log-rank test. g–i Scatter plots showing the Spearman’s correlation between AGR2 and three epithelium-related genes (CDH1, CTNNA1, CTNNB1) in TCGA PRAD (n = 494) database. The Spearman’s correlation was analyzed by GEPIA. j Spearman’s Correlation analysis between AGR2 and EMT-related genes (CDH1, CTNNA1, CTNNB1, EHF, VIM) in PCMR. k, l WB analysis of <t>E-cadherin,</t> Vimentin expression levels in NC/AGR2-KD PC3 cells (k) and xenograft tissues (l)
Transition, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/transition/product/Cell Signaling Technology Inc
Average 97 stars, based on 1 article reviews
transition - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
hcc202 dr paul huang  (ATCC)
95
ATCC hcc202 dr paul huang
Fig. 4 AGR2-downregulation was an invasive biomarker in PCMR. a–d The AGR2 expression of BPH-versus tumor-derived primary cell in whole cell (a, b) and surface protein (c, d) lysates was evaluated employing LC-MS/MS (a, c) and western blotting (WB, b, d). The protein blot bands of WB were quantified utilizing gray scanning (ImageJ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Wilcoxon rank-sum test. e IHC staining of AGR2 in different pathological grades (n = 138). The representative AGR2 IHC results (left) performed on Gleason score (GS) 3 + 4, GS 4 + 5, GS 5 + 5 and BPH. The positive rate of AGR2 was analyzed among BPHs (n = 37), early stage of tumors (GS 6–7, n = 80) and late stage of tumors (GS 8–10, n = 49) (right). *p < 0.05 by Fisher’s Exact test. Scale bar, 200 μm. f Kaplan–Meier plots for disease-free survival (DFS) of TCGA-PRAD patients grouped by the median of AGR2 levels. Statistics calculated by Log-rank test. g–i Scatter plots showing the Spearman’s correlation between AGR2 and three epithelium-related genes (CDH1, CTNNA1, CTNNB1) in TCGA PRAD (n = 494) database. The Spearman’s correlation was analyzed by GEPIA. j Spearman’s Correlation analysis between AGR2 and EMT-related genes (CDH1, CTNNA1, CTNNB1, EHF, VIM) in PCMR. k, l WB analysis of <t>E-cadherin,</t> Vimentin expression levels in NC/AGR2-KD PC3 cells (k) and xenograft tissues (l)
Hcc202 Dr Paul Huang, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hcc202 dr paul huang/product/ATCC
Average 95 stars, based on 1 article reviews
hcc202 dr paul huang - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
mcf 7 breast cancer cells  (ATCC)
99
ATCC mcf 7 breast cancer cells
Fig. 4 AGR2-downregulation was an invasive biomarker in PCMR. a–d The AGR2 expression of BPH-versus tumor-derived primary cell in whole cell (a, b) and surface protein (c, d) lysates was evaluated employing LC-MS/MS (a, c) and western blotting (WB, b, d). The protein blot bands of WB were quantified utilizing gray scanning (ImageJ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Wilcoxon rank-sum test. e IHC staining of AGR2 in different pathological grades (n = 138). The representative AGR2 IHC results (left) performed on Gleason score (GS) 3 + 4, GS 4 + 5, GS 5 + 5 and BPH. The positive rate of AGR2 was analyzed among BPHs (n = 37), early stage of tumors (GS 6–7, n = 80) and late stage of tumors (GS 8–10, n = 49) (right). *p < 0.05 by Fisher’s Exact test. Scale bar, 200 μm. f Kaplan–Meier plots for disease-free survival (DFS) of TCGA-PRAD patients grouped by the median of AGR2 levels. Statistics calculated by Log-rank test. g–i Scatter plots showing the Spearman’s correlation between AGR2 and three epithelium-related genes (CDH1, CTNNA1, CTNNB1) in TCGA PRAD (n = 494) database. The Spearman’s correlation was analyzed by GEPIA. j Spearman’s Correlation analysis between AGR2 and EMT-related genes (CDH1, CTNNA1, CTNNB1, EHF, VIM) in PCMR. k, l WB analysis of <t>E-cadherin,</t> Vimentin expression levels in NC/AGR2-KD PC3 cells (k) and xenograft tissues (l)
Mcf 7 Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mcf 7 breast cancer cells/product/ATCC
Average 99 stars, based on 1 article reviews
mcf 7 breast cancer cells - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
antibodies specific for e-cadherin, n-cadherin, vimentin, snail, mmp-2, mmp-9, akt, p-akt, pi3k, p-pi3k, and β-actin (β-actin)  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc antibodies specific for e-cadherin, n-cadherin, vimentin, snail, mmp-2, mmp-9, akt, p-akt, pi3k, p-pi3k, and β-actin (β-actin)
Fig. 4 AGR2-downregulation was an invasive biomarker in PCMR. a–d The AGR2 expression of BPH-versus tumor-derived primary cell in whole cell (a, b) and surface protein (c, d) lysates was evaluated employing LC-MS/MS (a, c) and western blotting (WB, b, d). The protein blot bands of WB were quantified utilizing gray scanning (ImageJ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Wilcoxon rank-sum test. e IHC staining of AGR2 in different pathological grades (n = 138). The representative AGR2 IHC results (left) performed on Gleason score (GS) 3 + 4, GS 4 + 5, GS 5 + 5 and BPH. The positive rate of AGR2 was analyzed among BPHs (n = 37), early stage of tumors (GS 6–7, n = 80) and late stage of tumors (GS 8–10, n = 49) (right). *p < 0.05 by Fisher’s Exact test. Scale bar, 200 μm. f Kaplan–Meier plots for disease-free survival (DFS) of TCGA-PRAD patients grouped by the median of AGR2 levels. Statistics calculated by Log-rank test. g–i Scatter plots showing the Spearman’s correlation between AGR2 and three epithelium-related genes (CDH1, CTNNA1, CTNNB1) in TCGA PRAD (n = 494) database. The Spearman’s correlation was analyzed by GEPIA. j Spearman’s Correlation analysis between AGR2 and EMT-related genes (CDH1, CTNNA1, CTNNB1, EHF, VIM) in PCMR. k, l WB analysis of <t>E-cadherin,</t> Vimentin expression levels in NC/AGR2-KD PC3 cells (k) and xenograft tissues (l)
Antibodies Specific For E Cadherin, N Cadherin, Vimentin, Snail, Mmp 2, Mmp 9, Akt, P Akt, Pi3k, P Pi3k, And β Actin (β Actin), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies specific for e-cadherin, n-cadherin, vimentin, snail, mmp-2, mmp-9, akt, p-akt, pi3k, p-pi3k, and β-actin (β-actin)/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
antibodies specific for e-cadherin, n-cadherin, vimentin, snail, mmp-2, mmp-9, akt, p-akt, pi3k, p-pi3k, and β-actin (β-actin) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
rwpe 1 atcc crl 11609 huamn vcap atcc crl 2876 human  (ATCC)
99
ATCC rwpe 1 atcc crl 11609 huamn vcap atcc crl 2876 human
Fig. 4 AGR2-downregulation was an invasive biomarker in PCMR. a–d The AGR2 expression of BPH-versus tumor-derived primary cell in whole cell (a, b) and surface protein (c, d) lysates was evaluated employing LC-MS/MS (a, c) and western blotting (WB, b, d). The protein blot bands of WB were quantified utilizing gray scanning (ImageJ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Wilcoxon rank-sum test. e IHC staining of AGR2 in different pathological grades (n = 138). The representative AGR2 IHC results (left) performed on Gleason score (GS) 3 + 4, GS 4 + 5, GS 5 + 5 and BPH. The positive rate of AGR2 was analyzed among BPHs (n = 37), early stage of tumors (GS 6–7, n = 80) and late stage of tumors (GS 8–10, n = 49) (right). *p < 0.05 by Fisher’s Exact test. Scale bar, 200 μm. f Kaplan–Meier plots for disease-free survival (DFS) of TCGA-PRAD patients grouped by the median of AGR2 levels. Statistics calculated by Log-rank test. g–i Scatter plots showing the Spearman’s correlation between AGR2 and three epithelium-related genes (CDH1, CTNNA1, CTNNB1) in TCGA PRAD (n = 494) database. The Spearman’s correlation was analyzed by GEPIA. j Spearman’s Correlation analysis between AGR2 and EMT-related genes (CDH1, CTNNA1, CTNNB1, EHF, VIM) in PCMR. k, l WB analysis of <t>E-cadherin,</t> Vimentin expression levels in NC/AGR2-KD PC3 cells (k) and xenograft tissues (l)
Rwpe 1 Atcc Crl 11609 Huamn Vcap Atcc Crl 2876 Human, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rwpe 1 atcc crl 11609 huamn vcap atcc crl 2876 human/product/ATCC
Average 99 stars, based on 1 article reviews
rwpe 1 atcc crl 11609 huamn vcap atcc crl 2876 human - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
normal huan intestinal epithelial cell line hiec  (ATCC)
97
ATCC normal huan intestinal epithelial cell line hiec
Fig. 4 AGR2-downregulation was an invasive biomarker in PCMR. a–d The AGR2 expression of BPH-versus tumor-derived primary cell in whole cell (a, b) and surface protein (c, d) lysates was evaluated employing LC-MS/MS (a, c) and western blotting (WB, b, d). The protein blot bands of WB were quantified utilizing gray scanning (ImageJ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Wilcoxon rank-sum test. e IHC staining of AGR2 in different pathological grades (n = 138). The representative AGR2 IHC results (left) performed on Gleason score (GS) 3 + 4, GS 4 + 5, GS 5 + 5 and BPH. The positive rate of AGR2 was analyzed among BPHs (n = 37), early stage of tumors (GS 6–7, n = 80) and late stage of tumors (GS 8–10, n = 49) (right). *p < 0.05 by Fisher’s Exact test. Scale bar, 200 μm. f Kaplan–Meier plots for disease-free survival (DFS) of TCGA-PRAD patients grouped by the median of AGR2 levels. Statistics calculated by Log-rank test. g–i Scatter plots showing the Spearman’s correlation between AGR2 and three epithelium-related genes (CDH1, CTNNA1, CTNNB1) in TCGA PRAD (n = 494) database. The Spearman’s correlation was analyzed by GEPIA. j Spearman’s Correlation analysis between AGR2 and EMT-related genes (CDH1, CTNNA1, CTNNB1, EHF, VIM) in PCMR. k, l WB analysis of <t>E-cadherin,</t> Vimentin expression levels in NC/AGR2-KD PC3 cells (k) and xenograft tissues (l)
Normal Huan Intestinal Epithelial Cell Line Hiec, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/normal huan intestinal epithelial cell line hiec/product/ATCC
Average 97 stars, based on 1 article reviews
normal huan intestinal epithelial cell line hiec - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
hela ace2 stable cell line  (ATCC)
99
ATCC hela ace2 stable cell line
Fig. 4 AGR2-downregulation was an invasive biomarker in PCMR. a–d The AGR2 expression of BPH-versus tumor-derived primary cell in whole cell (a, b) and surface protein (c, d) lysates was evaluated employing LC-MS/MS (a, c) and western blotting (WB, b, d). The protein blot bands of WB were quantified utilizing gray scanning (ImageJ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Wilcoxon rank-sum test. e IHC staining of AGR2 in different pathological grades (n = 138). The representative AGR2 IHC results (left) performed on Gleason score (GS) 3 + 4, GS 4 + 5, GS 5 + 5 and BPH. The positive rate of AGR2 was analyzed among BPHs (n = 37), early stage of tumors (GS 6–7, n = 80) and late stage of tumors (GS 8–10, n = 49) (right). *p < 0.05 by Fisher’s Exact test. Scale bar, 200 μm. f Kaplan–Meier plots for disease-free survival (DFS) of TCGA-PRAD patients grouped by the median of AGR2 levels. Statistics calculated by Log-rank test. g–i Scatter plots showing the Spearman’s correlation between AGR2 and three epithelium-related genes (CDH1, CTNNA1, CTNNB1) in TCGA PRAD (n = 494) database. The Spearman’s correlation was analyzed by GEPIA. j Spearman’s Correlation analysis between AGR2 and EMT-related genes (CDH1, CTNNA1, CTNNB1, EHF, VIM) in PCMR. k, l WB analysis of <t>E-cadherin,</t> Vimentin expression levels in NC/AGR2-KD PC3 cells (k) and xenograft tissues (l)
Hela Ace2 Stable Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hela ace2 stable cell line/product/ATCC
Average 99 stars, based on 1 article reviews
hela ace2 stable cell line - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


SERPINB5 knockdown suppresses the epithelial‐mesenchymal transition (EMT) of lung adenocarcinoma (LUAD) cells (a) Immunofluorescence staining showed the changes in the expression of EMT‐associated genes E‐cadherin (green) and vimentin (red) in LUAD cells. Nuclei were counterstained with DAPI (blue). (b) Western blot assay of the expression of EMT markers in LUAD cells transfected with si‐SERPINB5.

Journal: Thoracic Cancer

Article Title: SERPINB5 is a prognostic biomarker and promotes proliferation, metastasis and epithelial‐mesenchymal transition ( EMT) in lung adenocarcinoma

doi: 10.1111/1759-7714.15013

Figure Lengend Snippet: SERPINB5 knockdown suppresses the epithelial‐mesenchymal transition (EMT) of lung adenocarcinoma (LUAD) cells (a) Immunofluorescence staining showed the changes in the expression of EMT‐associated genes E‐cadherin (green) and vimentin (red) in LUAD cells. Nuclei were counterstained with DAPI (blue). (b) Western blot assay of the expression of EMT markers in LUAD cells transfected with si‐SERPINB5.

Article Snippet: Anti‐SERPINB5 was purchased from Immunoway Company (catalog no.: YT2657, 1:1000), and anti‐SNAIL (ER1706‐22, 1:1000), anti‐N‐cadherin (ET1607‐37, 1:1000), anti‐vimentin (EM0401, 1:1000) and anti‐E‐cadherin (ET1607‐75, 1:1000) were purchased from Hangzhou HuaAn Biotechnology.

Techniques: Immunofluorescence, Staining, Expressing, Western Blot, Transfection

Fig. 4 AGR2-downregulation was an invasive biomarker in PCMR. a–d The AGR2 expression of BPH-versus tumor-derived primary cell in whole cell (a, b) and surface protein (c, d) lysates was evaluated employing LC-MS/MS (a, c) and western blotting (WB, b, d). The protein blot bands of WB were quantified utilizing gray scanning (ImageJ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Wilcoxon rank-sum test. e IHC staining of AGR2 in different pathological grades (n = 138). The representative AGR2 IHC results (left) performed on Gleason score (GS) 3 + 4, GS 4 + 5, GS 5 + 5 and BPH. The positive rate of AGR2 was analyzed among BPHs (n = 37), early stage of tumors (GS 6–7, n = 80) and late stage of tumors (GS 8–10, n = 49) (right). *p < 0.05 by Fisher’s Exact test. Scale bar, 200 μm. f Kaplan–Meier plots for disease-free survival (DFS) of TCGA-PRAD patients grouped by the median of AGR2 levels. Statistics calculated by Log-rank test. g–i Scatter plots showing the Spearman’s correlation between AGR2 and three epithelium-related genes (CDH1, CTNNA1, CTNNB1) in TCGA PRAD (n = 494) database. The Spearman’s correlation was analyzed by GEPIA. j Spearman’s Correlation analysis between AGR2 and EMT-related genes (CDH1, CTNNA1, CTNNB1, EHF, VIM) in PCMR. k, l WB analysis of E-cadherin, Vimentin expression levels in NC/AGR2-KD PC3 cells (k) and xenograft tissues (l)

Journal: Signal transduction and targeted therapy

Article Title: Integrative multi-omics and drug-response characterization of patient-derived prostate cancer primary cells.

doi: 10.1038/s41392-023-01393-9

Figure Lengend Snippet: Fig. 4 AGR2-downregulation was an invasive biomarker in PCMR. a–d The AGR2 expression of BPH-versus tumor-derived primary cell in whole cell (a, b) and surface protein (c, d) lysates was evaluated employing LC-MS/MS (a, c) and western blotting (WB, b, d). The protein blot bands of WB were quantified utilizing gray scanning (ImageJ). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Wilcoxon rank-sum test. e IHC staining of AGR2 in different pathological grades (n = 138). The representative AGR2 IHC results (left) performed on Gleason score (GS) 3 + 4, GS 4 + 5, GS 5 + 5 and BPH. The positive rate of AGR2 was analyzed among BPHs (n = 37), early stage of tumors (GS 6–7, n = 80) and late stage of tumors (GS 8–10, n = 49) (right). *p < 0.05 by Fisher’s Exact test. Scale bar, 200 μm. f Kaplan–Meier plots for disease-free survival (DFS) of TCGA-PRAD patients grouped by the median of AGR2 levels. Statistics calculated by Log-rank test. g–i Scatter plots showing the Spearman’s correlation between AGR2 and three epithelium-related genes (CDH1, CTNNA1, CTNNB1) in TCGA PRAD (n = 494) database. The Spearman’s correlation was analyzed by GEPIA. j Spearman’s Correlation analysis between AGR2 and EMT-related genes (CDH1, CTNNA1, CTNNB1, EHF, VIM) in PCMR. k, l WB analysis of E-cadherin, Vimentin expression levels in NC/AGR2-KD PC3 cells (k) and xenograft tissues (l)

Article Snippet: After blocking membranes with 10% non-fat dried milk in phosphate-buffered saline and 0.1% Tween 20 solution, the following primary antibodies were incubated overnight at 4 °C with the membranes: Phospho-AKT (CST, 4060), AKT (CST, 4691), Phospho-c-MET (CST, 3077), c-MET (CST, 3127), Phospho-ALK (CST, 3983), ALK (CST, 3633), AMACR (Abcam, ab246927), AR (Abcam, ab268062), CK5 (Abcam, ab52635), E-cadherin (HuaAn, EM0502), Vimentin (HuaAn, EM0401), AGR2 (Proteintech, 12275-1- AP), Tubulin (Sigma-Aldrich, T6793), GAPDH (Proteintech, 10494-1- AP).

Techniques: Biomarker Discovery, Expressing, Derivative Assay, Liquid Chromatography with Mass Spectroscopy, Western Blot, Immunohistochemistry